Huachen AI Parking Surges 82% Premarket on Nasdaq Compliance Hopes
Markets Daniel Marsh

Huachen AI Parking Surges 82% Premarket on Nasdaq Compliance Hopes

Huachen AI Parking Management shares jumped 82% in premarket trading Monday, driven by Nasdaq compliance buzz and a recent reverse stock split. The stock reached $10.10 with volumes far above average.

HCAI
HIVE Digital Soars on C$3.5B AI Data Center Plan in Toronto
Technology Sarah Chen

HIVE Digital Soars on C$3.5B AI Data Center Plan in Toronto

HIVE Digital Technologies shares surged 33% in Nasdaq pre-market after its BUZZ HPC unit unveiled plans for a 320 MW AI infrastructure site near Toronto, with a C$3.5 billion investment target.

HIVE
T1 Energy Rises Premarket as Shareholder Vote on Capital Hike Nears
Markets Daniel Marsh

T1 Energy Rises Premarket as Shareholder Vote on Capital Hike Nears

T1 Energy Inc. stock traded up to $6.56 premarket Monday after closing at $5.67 Friday, as the company seeks shareholder approval to double authorized shares to 1 billion for its G2_Austin solar cell plant.

AI Data Center Boom Drives $66.8B NextEra-Dominion Merger
Markets Daniel Marsh

AI Data Center Boom Drives $66.8B NextEra-Dominion Merger

NextEra Energy is buying Dominion Energy for $66.8 billion in stock, forming the largest regulated electric utility globally to power AI data centers.

NEE D SO DUK
Bloom Energy Attracts Institutional Cash on AI Data Center Demand; Scalability Test Looms
Technology Sarah Chen

Bloom Energy Attracts Institutional Cash on AI Data Center Demand; Scalability Test Looms

World Investment Advisors and other institutions have taken stakes in Bloom Energy as the fuel-cell maker benefits from AI data center power demand. However, the company faces hurdles in scaling and execution.

BE ORCL PLUG FCEL BLDP AEP
GeoVax Shares Surge Pre-Market on Mpox Vaccine Trial Plans
Markets Daniel Marsh

GeoVax Shares Surge Pre-Market on Mpox Vaccine Trial Plans

GeoVax Labs shares surged pre-market Monday after announcing plans for a Phase 3 trial of its GEO-MVA mpox vaccine, though cash and funding risks remain key issues.

GOVX
Baidu Surges on AI Cloud Strength Despite Advertising Decline
Earnings James Calloway

Baidu Surges on AI Cloud Strength Despite Advertising Decline

Baidu's U.S.-listed shares rallied over 3% premarket as Q1 revenue topped forecasts, with AI cloud revenue surging 49% to offset a 22% drop in online marketing.

BIDU BABA
Crude Surge Puts Ethereum Under Pressure, Lee Warns of Macro Headwinds
Crypto Sarah Chen

Crude Surge Puts Ethereum Under Pressure, Lee Warns of Macro Headwinds

Ether fell to ~$2,100 as oil's jump above $100 reignited inflation fears. Fundstrat's Tom Lee flags crude as Ethereum's top headwind, with record negative correlation.

IBIT
Cisco's AI Surge Lifts Nokia; Earnings Test Looms
Technology Sarah Chen

Cisco's AI Surge Lifts Nokia; Earnings Test Looms

Nokia shares rose 1.2% after Cisco's $5.3B AI orders boosted networking stocks. Nokia's Q1 AI/cloud sales jumped 49%, but high valuation and competition keep the bar high.

CSCO NVDA LMT
Redwire Stock Holds Steady After 27% Rally, Focus Shifts to Defense Showcase
Markets Daniel Marsh

Redwire Stock Holds Steady After 27% Rally, Focus Shifts to Defense Showcase

Redwire shares traded flat Monday after a 27% rally last week, as the market awaits updates from the SOF Week defense event in Tampa and assesses the company's $498.1 million backlog.

RDW
XRP Retreats to $1.38 Amid Broad Crypto Selloff Despite ETF Inflows
Crypto Sarah Chen

XRP Retreats to $1.38 Amid Broad Crypto Selloff Despite ETF Inflows

XRP slid to $1.38 on Monday, down 2.29%, as a broad crypto selloff erased gains from last week. Despite $60.5M in spot ETF inflows, the token extended losses, with traders watching Fed minutes and US crypto legislation.

IBIT
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Markets Daniel Marsh

Regeneron Shares Slide After Melanoma Combo Misses Key Goal

Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.

REGN MRK BMY